Last Price$0.81NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change+0.01(1.69%)
Bid (Size)$0.80 (10)
Ask (Size)$0.82 (9)
Day Low / High$0.78 - 0.83
Volume2.2 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/30/2022


Sesen Bio Inc ( NASDAQ )

Price: $0.81
Change: +0.01 (1.69%)
Volume: 2.2 M
4:00PM ET 6/30/2022

Omeros Corp ( NASDAQ )

Price: $2.75
Change: +0.09 (3.38%)
Volume: 510.5 K
4:00PM ET 6/30/2022

Fennec Pharmaceuticals Inc ( NASDAQ )

Price: $5.58
Change: -0.19 (3.29%)
Volume: 6.8 K
3:58PM ET 6/30/2022

Oramed Pharmaceuticals Inc ( NASDAQ )

Price: $4.58
Change: +0.08 (1.78%)
Volume: 342.0 K
4:00PM ET 6/30/2022

Spectrum Pharmaceuticals Inc ( NASDAQ )

Price: $0.78
Change: -0.02 (2.86%)
Volume: 1.8 M
4:00PM ET 6/30/2022

Read more news Recent News

Sesen Bio Nixes Reverse Stock Split Plan; Shares Rise
11:04AM ET 6/17/2022 MT Newswires

Sesen Bio (SESN) said Friday that it is no longer seeking a reverse stock split of its common shares to avoid a potential delisting. The late-stage...

-- Earnings Flash (SESN) SESEN BIO Posts Q1 EPS $0.00
8:10AM ET 5/09/2022 MT Newswires


Sesen Bio Starts Reviewing Strategic Alternatives; Shares Surge
10:43AM ET 5/03/2022 MT Newswires

Sesen Bio (SESN) said Tuesday it has started reviewing strategic alternatives to maximize shareholder value. These options may include sale, merger,...

-- Earnings Flash (SESN) SESEN BIO Reports Q4 EPS $0.04
8:02AM ET 2/28/2022 MT Newswires


View all Commentary and Analysis

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
12:56PM ET 6/02/2022 Seeking Alpha

The State Of Biotech In 2022
4:04AM ET 1/03/2022 Seeking Alpha

Sesen Bio: Interesting Price Drop After CRL
3:10PM ET 11/24/2021 Seeking Alpha

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
9:11PM ET 11/16/2021 Seeking Alpha

Company Profile

Business DescriptionSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. View company web site for more details
Address245 First Street
Cambridge, Massachusetts 02142
Number of Employees24
Recent SEC Filing06/24/20224
President, Chief Executive Officer & DirectorThomas R. Cannell
Chief Financial Officer & TreasurerMonica Forbes
Finance DirectorStephanie Vigue
Head of ResearchJeannick Cizeau

Company Highlights

Price Open$0.80
Previous Close$0.80
52 Week Range$0.37 - 6.04
Market Capitalization$161.6 M
Shares Outstanding199.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings3.27
Earnings per Share-$0.02
Beta vs. S&P 500N/A
Net Profit Margin244.30%
Return on Equity39.16%

Analyst Ratings as of 03/01/2022

Consensus RecommendationConsensus Icon
Powered by Factset